Global Financial Private Capital LLC Has $11.68 Million Stake in Pfizer Inc. (PFE)
Global Financial Private Capital LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 116.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 322,038 shares of the biopharmaceutical company’s stock after buying an additional 173,534 shares during the period. Global Financial Private Capital LLC’s holdings in Pfizer were worth $11,684,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Ballew Advisors Inc bought a new position in shares of Pfizer in the first quarter worth approximately $102,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new position in shares of Pfizer in the first quarter worth approximately $132,000. Braun Bostich & Associates Inc. bought a new position in shares of Pfizer in the first quarter worth approximately $139,000. Bray Capital Advisors bought a new position in shares of Pfizer in the first quarter worth approximately $139,000. Finally, Clearwater Capital Advisors LLC bought a new position in shares of Pfizer in the first quarter worth approximately $156,000. Hedge funds and other institutional investors own 68.95% of the company’s stock.
PFE has been the topic of several research analyst reports. JPMorgan Chase & Co. restated a “$37.66” rating on shares of Pfizer in a research report on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, July 11th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research report on Tuesday, July 3rd. BMO Capital Markets restated a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a research report on Thursday, July 19th. Finally, Bank of America upped their price objective on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the company. Pfizer has an average rating of “Hold” and an average price target of $42.80.
Shares of NYSE PFE opened at $44.00 on Friday. Pfizer Inc. has a one year low of $33.20 and a one year high of $45.81. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. The company has a market cap of $262.34 billion, a price-to-earnings ratio of 16.60, a price-to-earnings-growth ratio of 2.23 and a beta of 0.96.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion for the quarter, compared to analysts’ expectations of $13.30 billion. During the same period last year, the business earned $0.67 earnings per share. The business’s quarterly revenue was up 4.4% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.